Physician profile

Howard C Lederman

Physical Medicine & Rehabilitation · Springfield, MA

NPI 1336125665

$1,545.67

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$363.13

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Organogenesis INC. $1,128.84 2019-2023 Puraply, Nushield
Integra Lifesciences Corporation $139.66 2019
Smith+Nephew, INC. $123.08 2019-2022
Kerecis Limited $40.91 2022
Molnlycke Health Care US, LLC $38.65 2019
Convatec INC. $20.98 2022
Aroa Biosurgery Incorporated $20.87 2019
Tactile Systems Technology INC $16.35 2021
Kci USA, INC. $16.33 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Howard C Lederman

$1,545.67

in general payments reported 2019-2025

Years
2019-2023
Top company
Organogenesis INC.

https://glasscript.com/doctor/242234/howard-c-lederman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.